L
Liv-Ingrid Odegardstuen
Researcher at GE Healthcare
Publications - 2
Citations - 1284
Liv-Ingrid Odegardstuen is an academic researcher from GE Healthcare. The author has contributed to research in topics: Cancer & Magnetic resonance imaging. The author has an hindex of 2, co-authored 2 publications receiving 1140 citations.
Papers
More filters
Journal ArticleDOI
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate
Sarah J. Nelson,John Kurhanewicz,Daniel B. Vigneron,Peder E. Z. Larson,Andrea L. Harzstark,Marcus Ferrone,Mark Van Criekinge,Jose W. Chang,Robert Bok,Ilwoo Park,Galen D. Reed,Lucas Carvajal,Eric J. Small,Pamela N. Munster,Vivian Weinberg,Jan Henrik Ardenkjær-Larsen,Albert P. Chen,Ralph E. Hurd,Liv-Ingrid Odegardstuen,Fraser Robb,James Tropp,Jonathan Alan Murray +21 more
TL;DR: This first-in-man imaging study evaluated the safety and feasibility of hyperpolarized [1-13C]pyruvate as an agent for noninvasively characterizing alterations in tumor metabolism for patients with prostate cancer and showed elevated levels of lactate, alanine, and bicarbonate in regions of biopsy-proven cancer.
Journal ArticleDOI
Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met
Jacobus Burggraaf,Ingrid M C Kamerling,Paul Gordon,Lenneke Schrier,Marieke L. de Kam,Andrea J Kales,Ragnar Bendiksen,Bard Indrevoll,Roger Bjerke,Siver Andreas Moestue,Siavash Yazdanfar,Alexandra M. J. Langers,Marit Swaerd-Nordmo,Geir Torheim,Madhuri V Warren,Hans Morreau,Philip W. Voorneveld,Tessa Buckle,Fijs W. B. van Leeuwen,Liv-Ingrid Odegardstuen,Grethe Tang Dalsgaard,Andrew Healey,James C. H. Hardwick +22 more
TL;DR: This first-in-human pilot study shows that molecular imaging using an intravenous fluorescent agent specific for c-Met is feasible and safe, and that it may enable the detection of polyps missed by other techniques.